Format
Sort by
Items per page

Send to

Choose Destination

Best matches for cannabidiol and gastrointestinal:

Search results

Items: 1 to 20 of 45

1.

A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential.

White CM.

J Clin Pharmacol. 2019 Feb 7. doi: 10.1002/jcph.1387. [Epub ahead of print] Review.

PMID:
30730563
2.

Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation.

Costiniuk CT, Saneei Z, Routy JP, Margolese S, Mandarino E, Singer J, Lebouché B, Cox J, Szabo J, Brouillette MJ, Klein MB, Chomont N, Jenabian MA.

BMJ Open. 2019 Jan 17;9(1):e024793. doi: 10.1136/bmjopen-2018-024793.

3.

Cannabis-based products for pediatric epilepsy: A systematic review.

Elliott J, DeJean D, Clifford T, Coyle D, Potter BK, Skidmore B, Alexander C, Repetski AE, Shukla V, McCoy B, Wells GA.

Epilepsia. 2019 Jan;60(1):6-19. doi: 10.1111/epi.14608. Epub 2018 Dec 4.

PMID:
30515765
4.

Cannabis for the treatment of Crohn's disease.

Kafil TS, Nguyen TM, MacDonald JK, Chande N.

Cochrane Database Syst Rev. 2018 Nov 8;11:CD012853. doi: 10.1002/14651858.CD012853.pub2. Review.

PMID:
30407616
6.

Cannabidiol for treating drug-resistant epilepsy in children: the New South Wales experience.

Chen KA, Farrar M, Cardamone M, Gill D, Smith R, Cowell CT, Truong L, Lawson JA.

Med J Aust. 2018 Aug 3;209(5):217-221. Epub 2018 Aug 13.

PMID:
30092753
7.

Cannabis for pediatric epilepsy: protocol for a living systematic review.

Elliott J, DeJean D, Clifford T, Coyle D, Potter B, Skidmore B, Alexander C, Repetski AE, McCoy B, Wells GA.

Syst Rev. 2018 Jul 18;7(1):95. doi: 10.1186/s13643-018-0761-2. Review.

8.

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis.

Irving PM, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, Hart A, Murray C, Lindsay JO, Taylor A, Barron R, Wright S.

Inflamm Bowel Dis. 2018 Mar 19;24(4):714-724. doi: 10.1093/ibd/izy002.

PMID:
29538683
9.

Cannabidiol Does Not Convert to Δ9-Tetrahydrocannabinol in an In Vivo Animal Model.

Wray L, Stott C, Jones N, Wright S.

Cannabis Cannabinoid Res. 2017 Dec 1;2(1):282-287. doi: 10.1089/can.2017.0032. eCollection 2017.

10.

Cannabinoids in Pain Management and Palliative Medicine.

Häuser W, Fitzcharles MA, Radbruch L, Petzke F.

Dtsch Arztebl Int. 2017 Sep 22;114(38):627-634. doi: 10.3238/arztebl.2017.0627. Review.

11.
12.

Even High Doses of Oral Cannabidol Do Not Cause THC-Like Effects in Humans: Comment on Merrick et al. Cannabis and Cannabinoid Research 2016;1(1):102-112; DOI: 10.1089/can.2015.0004.

Grotenhermen F, Russo E, Zuardi AW.

Cannabis Cannabinoid Res. 2017 Jan 1;2(1):1-4. doi: 10.1089/can.2016.0036. eCollection 2017.

13.

The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model.

Cherniakov I, Izgelov D, Domb AJ, Hoffman A.

Eur J Pharm Sci. 2017 Nov 15;109:21-30. doi: 10.1016/j.ejps.2017.07.003. Epub 2017 Jul 20.

PMID:
28736128
14.

Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?

Hasenoehrl C, Storr M, Schicho R.

Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):329-337. doi: 10.1080/17474124.2017.1292851. Epub 2017 Feb 16. Review.

15.

Cannabidiol: a potential treatment for post Ebola syndrome?

Reznik SE, Gardner EL, Ashby CR Jr.

Int J Infect Dis. 2016 Nov;52:74-76. doi: 10.1016/j.ijid.2016.09.020. Epub 2016 Sep 26.

16.

Abnormal cannabidiol attenuates experimental colitis in mice, promotes wound healing and inhibits neutrophil recruitment.

Krohn RM, Parsons SA, Fichna J, Patel KD, Yates RM, Sharkey KA, Storr MA.

J Inflamm (Lond). 2016 Jul 14;13:21. doi: 10.1186/s12950-016-0129-0. eCollection 2016.

17.

Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid.

Merrick J, Lane B, Sebree T, Yaksh T, O'Neill C, Banks SL.

Cannabis Cannabinoid Res. 2016 Apr 1;1(1):102-112. doi: 10.1089/can.2015.0004. eCollection 2016.

18.

CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience.

Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S, Nissenkorn A, Yosef OB, Hyman E, Granot D, Dor M, Lerman-Sagie T, Ben-Zeev B.

Seizure. 2016 Feb;35:41-4. doi: 10.1016/j.seizure.2016.01.004. Epub 2016 Jan 6.

19.

Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis.

Hammell DC, Zhang LP, Ma F, Abshire SM, McIlwrath SL, Stinchcomb AL, Westlund KN.

Eur J Pain. 2016 Jul;20(6):936-48. doi: 10.1002/ejp.818. Epub 2015 Oct 30.

20.

Endocannabinoids and the Digestive Tract and Bladder in Health and Disease.

Izzo AA, Muccioli GG, Ruggieri MR, Schicho R.

Handb Exp Pharmacol. 2015;231:423-47. doi: 10.1007/978-3-319-20825-1_15. Review.

PMID:
26408170

Supplemental Content

Loading ...
Support Center